Stevanato Group Partners with Bexson Biomedical on a Wearable Drug Delivery Device

News
Article

The companies will work together to produce a wearable device that can subcutaneously deliver ketamine therapy as a non-opioid pain treatment.

Stevanato Group, an Italian glass primary packaging producer, announced on Sept. 21, 2020 that it has signed an agreement with Bexson Biomedical, a research-stage company, for the development of the SG EZ-be Pod, a wearable drug delivery device for Bexson’s proprietary ketamine formulation, BB106.

Under the terms of the agreement, the companies will work together to produce a small, wearable and programable device that can subcutaneously deliver the ketamine therapy to patients looking for a non-opioid treatment for chronic and acute pain types, a Stevanato press release said.

“In the midst of a pandemic health crisis and evidence of increasing opioid addiction and overdoses, there has never been a greater need for effective non-opioid pain management. Stevanato Group has the ideal technology to deliver Bexson’s BB106 subcutaneous ketamine formulation,” said Gregg Peterson, Bexson’s co-founder and CEO, in the press release. “And beyond pain management, this partnership will create a true ketamine delivery platform that can be leveraged for a large number of future indications.”

“This design will support patient comfort with a discreet and intuitive device, and by utilizing our patented technologies, we address the importance of sustainability, while minimizing the overall cost per treatment,” said Steven Kaufman, vice-president of Drug Delivery Systems, Stevanato Group, in the press release. “This agreement with Bexson is a step forward for our device portfolio strategy and ongoing efforts to work closely with biotech and pharmaceutical companies as an integrated solution provider.”

Source: Stevanato

Recent Videos
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes
Related Content